ESMO 2026 Presidential Symposia: From Trial Results to Clinical Implications
Phase II Trial Shows Promising Pathologic Responses With Neoadjuvant Nivolumab and Chemotherapy in Salivary Gland Cancer
OncoDaily and Natera Present “Seismic Shift: Innovations in MRD Testing and Pathology”
NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer
ESMO 2026: What’s New in Melanoma Immunotherapy?
High CA-125 Levels: Causes, Normal Range and Cancer Risk
A National Multidisciplinary BC Course Has Trained 180 Clinicians Across Mongolia - UICC
Sara Tolaney: Breast Cancer Insights From ESMO 2026
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
